Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
NCT07449039
Summary
This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes. Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.
Eligibility
Inclusion Criteria: * Prenatal care at UCLA Health * Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica * Confirmed gestational diabetes diagnosis based on 2-step approach * Maternal age \>= 18 years Exclusion Criteria: * Pre-gestational diabetes (T1DM or T2DM) * Multifetal gestation * Intra-amniotic infection by clinical criteria * Postpartum hemorrhage * Maternal ICU admission * Known allergy to medical-grade adhesive * Presence of skin lesions at anticipated CGM application site * Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial * Metformin use * Steroid use * Terbutaline use within 4 hours of delivery * Cystic fibrosis * MODY (mature onset of diabetes in the young)
Conditions2
Locations1 site
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07449039